[Advances in researches on hormonal refractory prostate cancer].
In China, the incidence of prostate cancer has been increasing in recent years. Hormonal therapy has been the mainstay of the therapeutic options for metastatic diseases for many years. But many metastatic tumors progress at a median of two to five years and become hormonal refractory prostate cancer (HRPC). This article summarizes in the advances of diagnostic criteria, molecular biological features, prediction markers, new therapeutic agents and further researches to be undertaken concerning HRPC.
Song
Hai-zhu
HZ
Department of Oncology, Nanjing General Hospital of Nanjing Command, Nanjing, Jiangsu 210002, China. songhaizhu@163.com
Chen
Long-bang
LB
D000368:Aged; D000726:Androgen Antagonists / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000032:analysis; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
D000726:Androgen Antagonists; D014408:Biomarkers, Tumor